While urokinase plasminogen activator (uPA)-activated PAR1 demonstrably attenuates inflammatory osteoclastogenesis, a process essential for bone destruction in RA [175], the picture with thrombin–PAR1 interaction is more complex. The gene discussed is PLAU; the disease is rheumatoid arthritis.